Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.28
+0.46 (+1.65%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
↗
October 08, 2026
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
Via
The Motley Fool
Topics
Intellectual Property
2 Growth Stocks to Buy in October
↗
October 08, 2026
Grail and Veeva Systems could be well insulated from near-term headwinds.
Via
The Motley Fool
Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next.
↗
October 08, 2026
Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.
Via
The Motley Fool
Topics
Intellectual Property
Pfizer Stock: Buy, Sell, or Hold?
↗
October 07, 2026
The company is entering what could be a particularly challenging period.
Via
The Motley Fool
Topics
Intellectual Property
D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026?
↗
October 07, 2026
D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.
Via
The Motley Fool
Topics
Supply Chain
Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy.
↗
October 07, 2026
Buffett thinks many stocks are too hot to touch right now, but these three aren't.
Via
The Motley Fool
Topics
Artificial Intelligence
Energy
1 Healthcare Stock with Competitive Advantages and 2 We Find Risky
October 07, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Via
StockStory
3 of the Best Dividend Stocks to Buy in October 2026
↗
October 06, 2026
A couple of the stocks on this list pay more than 6% in dividends.
Via
The Motley Fool
Topics
Economy
Intellectual Property
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges
October 06, 2026
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Via
StockStory
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock
↗
October 05, 2026
The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.
Via
The Motley Fool
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now
↗
October 05, 2026
Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.
Via
The Motley Fool
Topics
Intellectual Property
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study
↗
October 05, 2026
Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.
Via
Investor's Business Daily
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
↗
October 05, 2026
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend...
Via
The Motley Fool
Topics
Intellectual Property
Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.
↗
October 05, 2026
Put your money to work generating dividend income with these stocks.
Via
The Motley Fool
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
↗
October 04, 2026
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.
Via
The Motley Fool
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield
↗
October 04, 2026
The crowd is looking at the next couple of years. It should be looking five years into the future.
Via
The Motley Fool
Topics
Intellectual Property
3 Dirt Cheap Dividend Stocks Worth Buying in October
↗
October 04, 2026
There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.
Via
The Motley Fool
Topics
Intellectual Property
My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October
↗
October 04, 2026
These stocks offer juicy yields and attractive risk-reward profiles.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Energy
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
↗
October 03, 2026
With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.
Via
MarketBeat
Topics
Bonds
Retirement
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?
↗
October 03, 2026
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Via
The Motley Fool
Topics
Intellectual Property
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP
↗
October 02, 2026
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.
Via
The Motley Fool
Topics
ETFs
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
↗
October 02, 2026
Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.
Via
The Motley Fool
Topics
Intellectual Property
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.
↗
October 02, 2026
Pfizer has been going through a period of transition.
Via
The Motley Fool
Topics
Earnings
Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive
↗
October 01, 2026
Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.
Via
The Motley Fool
Topics
Economy
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
↗
October 01, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...
Via
MarketBeat
Topics
ETFs
With the Market Flashing Warning Signs Not Seen Since the Dot-Com Bust, Is Pfizer's 6% Yield a Safe Haven or a Trap?
↗
September 29, 2026
While Pfizer's dividend looks like a trap, its strong balance sheet and low valuation make it safer.
Via
The Motley Fool
Topics
Intellectual Property
World Trade
Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now
↗
September 29, 2026
Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.
Via
The Motley Fool
Topics
Intellectual Property
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
↗
September 28, 2026
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
Via
The Motley Fool
5 Dividend Stocks Yielding Over 5% With Fortress Financial Profiles to Buy Now
↗
September 27, 2026
These high-yielding stocks offer very durable dividends.
Via
The Motley Fool
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
↗
September 27, 2026
Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.
Via
The Motley Fool
Topics
Bonds
Economy
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today